The Australian Medical Association Limited and state AMA entities comply with the Privacy Act 1988. Please refer to the AMA Privacy Policy to understand our commitment to you and information on how we store and protect your data.




AMA submission to the TGA on proposed scheduling changes to Finasteride and Sanguinarine

08 May 2019

The AMA opposes the down-scheduling of Finasteride from Schedule 4 to Schedule 3 due to potential risks to patients. The AMA supports the proposal to classify Sanguinarine as a Schedule 10 medicine which would effectively prohibit its sale, supply and use in Australia.

Published: 08 May 2019